Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.

Abstract

On average, there was a significant increase in lumbar spine aBMD percent change after 48 weeks of denosumab. There was no change in mobility parameters and no serious adverse events. Further trials are necessary to assess long-term side effects and efficacy.